Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

Neutralizing anti-drug antibodies in Fabry disease can inhibit endothelial enzyme uptake and activity.

Stappers F, Scharnetzki D, Schmitz B, Manikowski D, Brand SM, Grobe K, Lenders M, Brand E.

J Inherit Metab Dis. 2019 Oct 6. doi: 10.1002/jimd.12176. [Epub ahead of print]

PMID:
31587315
2.

Soluble adenylyl cyclase (sAC) regulates calcium signaling in the vascular endothelium.

Mewes M, Lenders M, Stappers F, Scharnetzki D, Nedele J, Fels J, Wedlich-Söldner R, Brand SM, Schmitz B, Brand E.

FASEB J. 2019 Oct 4:fj201900724R. doi: 10.1096/fj.201900724R. [Epub ahead of print]

PMID:
31585052
3.

Mutation-specific Fabry disease patient-derived cell model to evaluate the amenability to chaperone therapy.

Lenders M, Stappers F, Niemietz C, Schmitz B, Boutin M, Ballmaier PJ, Zibert A, Schmidt H, Brand SM, Auray-Blais C, Brand E.

J Med Genet. 2019 Aug;56(8):548-556. doi: 10.1136/jmedgenet-2019-106005. Epub 2019 Apr 22.

PMID:
31010832
4.

Effects of high-intensity interval training on microvascular glycocalyx and associated microRNAs.

Schmitz B, Niehues H, Lenders M, Thorwesten L, Klose A, Krüger M, Brand E, Brand SM.

Am J Physiol Heart Circ Physiol. 2019 Jun 1;316(6):H1538-H1551. doi: 10.1152/ajpheart.00751.2018. Epub 2019 Apr 12.

PMID:
30978133
5.

Genome-wide association study suggests impact of chromosome 10 rs139401390 on kidney function in patients with coronary artery disease.

Schmitz B, Kleber ME, Lenders M, Delgado GE, Engelbertz C, Huang J, Pavenstädt H, Breithardt G, Brand SM, März W, Brand E.

Sci Rep. 2019 Feb 26;9(1):2750. doi: 10.1038/s41598-019-39055-y.

6.

Dose-Dependent Effect of Enzyme Replacement Therapy on Neutralizing Antidrug Antibody Titers and Clinical Outcome in Patients with Fabry Disease.

Lenders M, Neußer LP, Rudnicki M, Nordbeck P, Canaan-Kühl S, Nowak A, Cybulla M, Schmitz B, Lukas J, Wanner C, Brand SM, Brand E.

J Am Soc Nephrol. 2018 Dec;29(12):2879-2889. doi: 10.1681/ASN.2018070740. Epub 2018 Nov 1.

PMID:
30385651
7.

Neutralizing anti-drug antibodies in Fabry disease have no obvious clinical impact?

Lenders M, Schmitz B, Brand SM, Brand E.

Orphanet J Rare Dis. 2018 Sep 29;13(1):171. doi: 10.1186/s13023-018-0916-1.

8.

Effects of Enzyme Replacement Therapy and Antidrug Antibodies in Patients with Fabry Disease.

Lenders M, Brand E.

J Am Soc Nephrol. 2018 Sep;29(9):2265-2278. doi: 10.1681/ASN.2018030329. Epub 2018 Aug 9. Review. No abstract available.

9.

ZFP226 is a novel artificial transcription factor for selective activation of tumor suppressor KIBRA.

Schelleckes K, Schmitz B, Lenders M, Mewes M, Brand SM, Brand E.

Sci Rep. 2018 Mar 9;8(1):4230. doi: 10.1038/s41598-018-22600-6.

10.

Characterization of drug-neutralizing antibodies in patients with Fabry disease during infusion.

Lenders M, Schmitz B, Brand SM, Foell D, Brand E.

J Allergy Clin Immunol. 2018 Jun;141(6):2289-2292.e7. doi: 10.1016/j.jaci.2017.12.1001. Epub 2018 Feb 5. No abstract available.

PMID:
29421273
11.

Corrigendum: Directionality of substrate translocation of the hemolysin A Type I secretion system.

Lenders MHH, Weidtkamp-Peters S, Kleinschrodt D, Jaeger KE, Smits SHJ, Schmitt L.

Sci Rep. 2018 Jan 8;8:46926. doi: 10.1038/srep46926.

12.

Fabry disease under enzyme replacement therapy-new insights in efficacy of different dosages.

Krämer J, Lenders M, Canaan-Kühl S, Nordbeck P, Üçeyler N, Blaschke D, Duning T, Reiermann S, Stypmann J, Brand SM, Gottschling T, Störk S, Wanner C, Sommer C, Brand E, Weidemann F.

Nephrol Dial Transplant. 2018 Aug 1;33(8):1362-1372. doi: 10.1093/ndt/gfx319.

PMID:
29186537
13.

Promoter methylation inhibits expression of tumor suppressor KIBRA in human clear cell renal cell carcinoma.

Schelleckes K, Schmitz B, Ciarimboli G, Lenders M, Pavenstädt HJ, Herrmann E, Brand SM, Brand E.

Clin Epigenetics. 2017 Oct 6;9:109. doi: 10.1186/s13148-017-0415-6. eCollection 2017.

14.

Blood-derived macrophages prone to accumulate lysosomal lipids trigger oxLDL-dependent murine hepatic inflammation.

Houben T, Oligschlaeger Y, Bitorina AV, Hendrikx T, Walenbergh SMA, Lenders MH, Gijbels MJJ, Verheyen F, Lütjohann D, Hofker MH, Binder CJ, Shiri-Sverdlov R.

Sci Rep. 2017 Oct 2;7(1):12550. doi: 10.1038/s41598-017-13058-z.

15.

Impact of immunosuppressive therapy on therapy-neutralizing antibodies in transplanted patients with Fabry disease.

Lenders M, Oder D, Nowak A, Canaan-Kühl S, Arash-Kaps L, Drechsler C, Schmitz B, Nordbeck P, Hennermann JB, Kampmann C, Reuter S, Brand SM, Wanner C, Brand E.

J Intern Med. 2017 Sep;282(3):241-253. doi: 10.1111/joim.12647. Epub 2017 Jul 26.

16.

Dose-Response of High-Intensity Training (HIT) on Atheroprotective miRNA-126 Levels.

Schmitz B, Schelleckes K, Nedele J, Thorwesten L, Klose A, Lenders M, Krüger M, Brand E, Brand SM.

Front Physiol. 2017 May 30;8:349. doi: 10.3389/fphys.2017.00349. eCollection 2017.

17.

Salt-induced Na+/K+-ATPase-α/β expression involves soluble adenylyl cyclase in endothelial cells.

Mewes M, Nedele J, Schelleckes K, Bondareva O, Lenders M, Kusche-Vihrog K, Schnittler HJ, Brand SM, Schmitz B, Brand E.

Pflugers Arch. 2017 Oct;469(10):1401-1412. doi: 10.1007/s00424-017-1999-6. Epub 2017 May 26.

PMID:
28550472
18.

Type I Protein Secretion-Deceptively Simple yet with a Wide Range of Mechanistic Variability across the Family.

Holland IB, Peherstorfer S, Kanonenberg K, Lenders M, Reimann S, Schmitt L.

EcoSal Plus. 2016 Dec;7(1). doi: 10.1128/ecosalplus.ESP-0019-2015. Review.

PMID:
28084193
19.

Renal function predicts long-term outcome on enzyme replacement therapy in patients with Fabry disease.

Lenders M, Schmitz B, Stypmann J, Duning T, Brand SM, Kurschat C, Brand E.

Nephrol Dial Transplant. 2017 Dec 1;32(12):2090-2097. doi: 10.1093/ndt/gfw334.

PMID:
27679524
20.

Physical Exercise in Patients with Fabry Disease - a Pilot Study.

Schmitz B, Thorwesten L, Lenders M, Duning T, Stypmann J, Brand E, Brand SM.

Int J Sports Med. 2016 Dec;37(13):1066-1072. Epub 2016 Sep 27.

PMID:
27676143
21.

In vivo quantification of the secretion rates of the hemolysin A Type I secretion system.

Lenders MH, Beer T, Smits SH, Schmitt L.

Sci Rep. 2016 Sep 12;6:33275. doi: 10.1038/srep33275.

22.

Multicenter Female Fabry Study (MFFS) - clinical survey on current treatment of females with Fabry disease.

Lenders M, Hennermann JB, Kurschat C, Rolfs A, Canaan-Kühl S, Sommer C, Üçeyler N, Kampmann C, Karabul N, Giese AK, Duning T, Stypmann J, Krämer J, Weidemann F, Brand SM, Wanner C, Brand E.

Orphanet J Rare Dis. 2016 Jun 29;11(1):88. doi: 10.1186/s13023-016-0473-4.

23.

Alpha-Galactosidase A p.A143T, a non-Fabry disease-causing variant.

Lenders M, Weidemann F, Kurschat C, Canaan-Kühl S, Duning T, Stypmann J, Schmitz B, Reiermann S, Krämer J, Blaschke D, Wanner C, Brand SM, Brand E.

Orphanet J Rare Dis. 2016 May 4;11(1):54. doi: 10.1186/s13023-016-0441-z.

24.

Effect of Burst Stimulation Evaluated in Patients Familiar With Spinal Cord Stimulation.

Tjepkema-Cloostermans MC, de Vos CC, Wolters R, Dijkstra-Scholten C, Lenders MW.

Neuromodulation. 2016 Jul;19(5):492-7. doi: 10.1111/ner.12429. Epub 2016 Apr 5.

PMID:
27059278
25.

Quality of life increases in patients with painful diabetic neuropathy following treatment with spinal cord stimulation.

Duarte RV, Andronis L, Lenders MW, de Vos CC.

Qual Life Res. 2016 Jul;25(7):1771-7. doi: 10.1007/s11136-015-1211-4. Epub 2015 Dec 22.

26.

Biophysical Characterization of Nucleophosmin Interactions with Human Immunodeficiency Virus Rev and Herpes Simplex Virus US11.

Nouri K, Moll JM, Milroy LG, Hain A, Dvorsky R, Amin E, Lenders M, Nagel-Steger L, Howe S, Smits SH, Hengel H, Schmitt L, Münk C, Brunsveld L, Ahmadian MR.

PLoS One. 2015 Dec 1;10(12):e0143634. doi: 10.1371/journal.pone.0143634. eCollection 2015.

27.

Differential response to endothelial epithelial sodium channel inhibition ex vivo correlates with arterial stiffness in humans.

Lenders M, Hofschröer V, Schmitz B, Kasprzak B, Rohlmann A, Missler M, Pavenstädt H, Oberleithner H, Brand SM, Kusche-Vihrog K, Brand E.

J Hypertens. 2015 Dec;33(12):2455-62. doi: 10.1097/HJH.0000000000000736.

PMID:
26378680
28.

Directionality of substrate translocation of the hemolysin A Type I secretion system.

Lenders MH, Weidtkamp-Peters S, Kleinschrodt D, Jaeger KE, Smits SH, Schmitt L.

Sci Rep. 2015 Jul 27;5:12470. doi: 10.1038/srep12470. Erratum in: Sci Rep. 2018 Jan 08;8:46926.

29.

Patients with Fabry Disease after Enzyme Replacement Therapy Dose Reduction and Switch-2-Year Follow-Up.

Lenders M, Canaan-Kühl S, Krämer J, Duning T, Reiermann S, Sommer C, Stypmann J, Blaschke D, Üçeyler N, Hense HW, Brand SM, Wanner C, Weidemann F, Brand E.

J Am Soc Nephrol. 2016 Mar;27(3):952-62. doi: 10.1681/ASN.2015030337. Epub 2015 Jul 16.

30.

Serum-Mediated Inhibition of Enzyme Replacement Therapy in Fabry Disease.

Lenders M, Stypmann J, Duning T, Schmitz B, Brand SM, Brand E.

J Am Soc Nephrol. 2016 Jan;27(1):256-64. doi: 10.1681/ASN.2014121226. Epub 2015 Apr 30.

31.

Thromboembolic events in Fabry disease and the impact of factor V Leiden.

Lenders M, Karabul N, Duning T, Schmitz B, Schelleckes M, Mesters R, Hense HW, Beck M, Brand SM, Brand E.

Neurology. 2015 Mar 10;84(10):1009-16. doi: 10.1212/WNL.0000000000001333. Epub 2015 Feb 6.

PMID:
25663229
32.

Cryptogenic stroke and small fiber neuropathy of unknown etiology in patients with alpha-galactosidase A -10T genotype.

Schelleckes M, Lenders M, Guske K, Schmitz B, Tanislav C, Ständer S, Metze D, Katona I, Weis J, Brand SM, Duning T, Brand E.

Orphanet J Rare Dis. 2014 Nov 26;9:178. doi: 10.1186/s13023-014-0178-5.

33.

Is preoperative pain duration important in spinal cord stimulation? A comparison between tonic and burst stimulation.

De Ridder D, Vancamp T, Lenders MW, De Vos CC, Vanneste S.

Neuromodulation. 2015 Jan;18(1):13-7; discussion 17. doi: 10.1111/ner.12253. Epub 2014 Oct 21.

PMID:
25334057
34.

Identification of genetic markers for treatment success in heart failure patients: insight from cardiac resynchronization therapy.

Schmitz B, De Maria R, Gatsios D, Chrysanthakopoulou T, Landolina M, Gasparini M, Campolo J, Parolini M, Sanzo A, Galimberti P, Bianchi M, Lenders M, Brand E, Parodi O, Lunati M, Brand SM.

Circ Cardiovasc Genet. 2014 Dec;7(6):760-70. doi: 10.1161/CIRCGENETICS.113.000384. Epub 2014 Sep 10.

PMID:
25210049
35.

Spinal cord stimulation in patients with painful diabetic neuropathy: a multicentre randomized clinical trial.

de Vos CC, Meier K, Zaalberg PB, Nijhuis HJ, Duyvendak W, Vesper J, Enggaard TP, Lenders MW.

Pain. 2014 Nov;155(11):2426-31. doi: 10.1016/j.pain.2014.08.031. Epub 2014 Aug 29.

PMID:
25180016
36.

Crystal structure of the ectoine hydroxylase, a snapshot of the active site.

Höppner A, Widderich N, Lenders M, Bremer E, Smits SH.

J Biol Chem. 2014 Oct 24;289(43):29570-83. doi: 10.1074/jbc.M114.576769. Epub 2014 Aug 29.

37.

A 2-center comparative study on tonic versus burst spinal cord stimulation: amount of responders and amount of pain suppression.

De Ridder D, Lenders MW, De Vos CC, Dijkstra-Scholten C, Wolters R, Vancamp T, Van Looy P, Van Havenbergh T, Vanneste S.

Clin J Pain. 2015 May;31(5):433-7. doi: 10.1097/AJP.0000000000000129.

PMID:
24977394
38.

Burst spinal cord stimulation evaluated in patients with failed back surgery syndrome and painful diabetic neuropathy.

de Vos CC, Bom MJ, Vanneste S, Lenders MW, de Ridder D.

Neuromodulation. 2014 Feb;17(2):152-9. doi: 10.1111/ner.12116. Epub 2013 Sep 24.

PMID:
24655043
39.

Patients with Fabry disease after enzyme replacement therapy dose reduction versus treatment switch.

Weidemann F, Krämer J, Duning T, Lenders M, Canaan-Kühl S, Krebs A, Guerrero González H, Sommer C, Üçeyler N, Niemann M, Störk S, Schelleckes M, Reiermann S, Stypmann J, Brand SM, Wanner C, Brand E.

J Am Soc Nephrol. 2014 Apr;25(4):837-49. doi: 10.1681/ASN.2013060585. Epub 2014 Feb 20.

40.

Chronic hibernating myocardium in sheep can occur without degenerating events and is reversed after revascularization.

Verheyen F, Racz R, Borgers M, Driesen RB, Lenders MH, Flameng WJ.

Cardiovasc Pathol. 2014 May-Jun;23(3):160-8. doi: 10.1016/j.carpath.2014.01.003. Epub 2014 Jan 10.

PMID:
24529701
41.

Soluble adenylyl cyclase in vascular endothelium: gene expression control of epithelial sodium channel-α, Na+/K+-ATPase-α/β, and mineralocorticoid receptor.

Schmitz B, Nedele J, Guske K, Maase M, Lenders M, Schelleckes M, Kusche-Vihrog K, Brand SM, Brand E.

Hypertension. 2014 Apr;63(4):753-61. doi: 10.1161/HYPERTENSIONAHA.113.02061. Epub 2014 Jan 13.

PMID:
24420537
42.

Molecular insights into type I secretion systems.

Lenders MH, Reimann S, Smits SH, Schmitt L.

Biol Chem. 2013 Nov;394(11):1371-84. doi: 10.1515/hsz-2013-0171. Review.

PMID:
23832956
43.

Multifocal white matter lesions associated with the D313Y mutation of the α-galactosidase A gene.

Lenders M, Duning T, Schelleckes M, Schmitz B, Stander S, Rolfs A, Brand SM, Brand E.

PLoS One. 2013;8(2):e55565. doi: 10.1371/journal.pone.0055565. Epub 2013 Feb 5.

44.

Subthalamic nucleus versus globus pallidus bilateral deep brain stimulation for advanced Parkinson's disease (NSTAPS study): a randomised controlled trial.

Odekerken VJ, van Laar T, Staal MJ, Mosch A, Hoffmann CF, Nijssen PC, Beute GN, van Vugt JP, Lenders MW, Contarino MF, Mink MS, Bour LJ, van den Munckhof P, Schmand BA, de Haan RJ, Schuurman PR, de Bie RM.

Lancet Neurol. 2013 Jan;12(1):37-44. doi: 10.1016/S1474-4422(12)70264-8. Epub 2012 Nov 16.

PMID:
23168021
45.

Down-regulation of small rubber particle protein expression affects integrity of rubber particles and rubber content in Taraxacum brevicorniculatum.

Hillebrand A, Post JJ, Wurbs D, Wahler D, Lenders M, Krzyzanek V, Prüfer D, Gronover CS.

PLoS One. 2012;7(7):e41874. doi: 10.1371/journal.pone.0041874. Epub 2012 Jul 23.

46.

Secretion of slow-folding proteins by a Type 1 secretion system.

Schwarz CK, Lenders MH, Smits SH, Schmitt L.

Bioengineered. 2012 Sep-Oct;3(5):289-92. doi: 10.4161/bioe.20712. Epub 2012 Jun 29.

47.

Using an E. coli Type 1 secretion system to secrete the mammalian, intracellular protein IFABP in its active form.

Schwarz CK, Landsberg CD, Lenders MH, Smits SH, Schmitt L.

J Biotechnol. 2012 Jun 15;159(3):155-61. doi: 10.1016/j.jbiotec.2012.02.005. Epub 2012 Feb 17.

PMID:
22366493
48.

Spinal cord stimulation with hybrid lead relieves pain in low back and legs.

de Vos CC, Dijkstra C, Lenders MW, Holsheimer J.

Neuromodulation. 2012 Mar-Apr;15(2):118-23; discussion 123. doi: 10.1111/j.1525-1403.2011.00404.x. Epub 2011 Nov 10.

PMID:
22074412
49.

Characterization of rubber particles and rubber chain elongation in Taraxacum koksaghyz.

Schmidt T, Lenders M, Hillebrand A, van Deenen N, Munt O, Reichelt R, Eisenreich W, Fischer R, Prüfer D, Gronover CS.

BMC Biochem. 2010 Feb 19;11:11. doi: 10.1186/1471-2091-11-11.

50.

Long-term superiority of subthalamic nucleus stimulation over pallidotomy in Parkinson disease.

Esselink RA, de Bie RM, de Haan RJ, Lenders MW, Nijssen PC, van Laar T, Schuurman PR, Bosch DA, Speelman JD.

Neurology. 2009 Jul 14;73(2):151-3. doi: 10.1212/WNL.0b013e3181ad536c. No abstract available.

PMID:
19597136

Supplemental Content

Loading ...
Support Center